Competitive Advantages:
Reduces colorectal cancer cell growth and proliferation, Does not harm healthy cells, Applicable as anti-atypical PKC therapy.
The subject invention pertains to methods of treating colorectal cancer by administering an atypical PKC inhibitor. The inhibitors of aPKC useful in the methods of the instant invention include ACPD, ICA-1, DNDA and s-Stat. Also provided are methods of measuring the susceptibility of colon cancer cells of a subject to inhibitors of aPKCs.USF scientists have discovered that by inhibiting PKC-iota and PKC-zeta with certain drugs (ACPD, DNDA and ICA-1), a significant decrease in cancer cell proliferation is shown. Furthermore, an additional protein kinase inhibitor (zeta-Stat) demonstrated an increase in colorectal cancer cell death without compromising normal colon cell health. This novel method could improve treatments in colorectal cancer.
Brochure
